Journal article · 2008 · Open access

Clinical Pharmacogenetics and Potential Application in Personalized Medicine

Shufeng Zhou, Yuan Ming Di, Elaine Chan, Yaomin Du, Vivian Chow, Charlie Changli Xue, Xinsheng Lai, Jiancheng Wang, Chun Guang Li, Min Tian, Wei Duan

Current Drug Metabolism, 9(8), 738–784 · Published 1 October 2008 · DOI 10.2174/138920008786049302

Open full textView at the publisherCite this paper

In brief

“Clinical Pharmacogenetics and Potential Application in Personalized Medicine” is a 2008 journal article by Shufeng Zhou and 10 co-authors, published in Current Drug Metabolism. OpenAlex counts 239 citations as of 21 November 2026, which puts it in the top 4% of works published in 2008 by citations. It is open access under a CC BY licence: the full text is free to read at Figshare.

Citations
239
Most cited in
2017 (17)
Field-weighted impact
14.75
Authors
11

Abstract

The current 'fixed-dosage strategy' approach to medicine, means there is much inter-individual variation in drug response. Pharmacogenetics is the study of how inter-individual variations in the DNA sequence of specific genes affect drug responses. This article will highlight current pharmacogenetic knowledge on important drug metabolizing enzymes, drug transporters and drug targets to understand interindividual variability in drug clearance and responses in clinical practice and potential use in personalized medicine. Polymorphisms in the cytochrome P450 (CYP) family may have had the most impact on the fate of pharmaceutical drugs. CYP2D6, CYP2C19 and CYP2C9 gene polymorphisms and gene duplications account for the most frequent variations in phase I metabolism of drugs since nearly 80% of drugs in use today are metabolised by these enzymes. Approximately 5% of Europeans and 1% of Asians lack CYP2D6 activity, and these individuals are known as poor metabolizers. CYP2C9 is another clinically significant drug metabolising enzyme that demonstrates genetic variants. Studies into CYP2C9 polymorphism have highlighted the importance of the CYP2C9*2 and CYP2C9*3 alleles. Extensive polymorphism also occurs in a majority of Phase II drug metabolizing enzymes. One of the most important polymorphisms is thiopurine S-methyl transferases (TPMT) that catalyzes the S-methylation of thiopurine drugs. With respect to drug transport polymorphism, the most extensively studied drug transporter is P-glycoprotein (P-gp/MDR1), but the current data on the clinical impact is limited. Polymorphisms in drug transporters may change drug's distribution, excretion and response. Recent advances in molecular research have revealed many of the genes that encode drug targets demonstrate genetic polymorphism. These variations, in many cases, have altered the targets sensitivity to the specific drug molecule and thus have a profound effect on drug efficacy and toxicity. For example, the beta (2)-adrenoreceptor, which is encoded by the ADRB2 gene, illustrates a clinically significant genetic variation in drug targets. The variable number tandem repeat polymorphisms in serotonin transporter (SERT/SLC6A4) gene are associated with response to antidepressants. The distribution of the common variant alleles of genes that encode drug metabolizing enzymes, drug transporters and drug targets has been found to vary among different populations. The promise of pharmacogenetics lies in its potential to identify the right drug at the right dose for the right individual. Drugs with a narrow therapeutic index are thought to benefit more from pharmacogenetic studies. For example, warfarin serves as a good practical example of how pharmacogenetics can be utilized prior to commencement of therapy in order to achieve maximum efficacy and minimum toxicity. As such, pharmacogenetics has the potential to achieve optimal quality use of medicines…

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Zhou, S., Di, Y. M., Chan, E., Du, Y., Chow, V., Xue, C. C., Lai, X., Wang, J., Li, C. G., Tian, M., & Duan, W. (2008). Clinical Pharmacogenetics and Potential Application in Personalized Medicine. Current Drug Metabolism, 9(8), 738–784. https://doi.org/10.2174/138920008786049302

MLA 9

Zhou, Shufeng, et al. “Clinical Pharmacogenetics and Potential Application in Personalized Medicine.” Current Drug Metabolism, vol. 9, no. 8, 2008, pp. 738–784. https://doi.org/10.2174/138920008786049302.

Chicago

Zhou, Shufeng, Yuan Ming Di, Elaine Chan, Yaomin Du, Vivian Chow, Charlie Changli Xue, Xinsheng Lai, et al. 2008. “Clinical Pharmacogenetics and Potential Application in Personalized Medicine.” Current Drug Metabolism 9 (8): 738–784. https://doi.org/10.2174/138920008786049302.

Harvard

Zhou, S. et al. (2008) ‘Clinical Pharmacogenetics and Potential Application in Personalized Medicine’, Current Drug Metabolism, 9(8), pp. 738–784. doi:10.2174/138920008786049302.

IEEE

S. Zhou et al., “Clinical Pharmacogenetics and Potential Application in Personalized Medicine,” Current Drug Metabolism, vol. 9, no. 8, pp. 738–784, 2008, doi: 10.2174/138920008786049302.

BibTeX

@article{zhou2008clinical,
  title     = {{Clinical Pharmacogenetics and Potential Application in Personalized Medicine}},
  author    = {Zhou, Shufeng and Di, Yuan Ming and Chan, Elaine and Du, Yaomin and Chow, Vivian and Xue, Charlie Changli and Lai, Xinsheng and Wang, Jiancheng and Li, Chun Guang and Tian, Min and Duan, Wei},
  journal   = {Current Drug Metabolism},
  year      = {2008},
  volume    = {9},
  number    = {8},
  pages     = {738--784},
  doi       = {10.2174/138920008786049302},
  url       = {https://doi.org/10.2174/138920008786049302}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
20171717
20181616
20191111
202077
202177
202255
202355
202499
202599
202644

Its field-weighted citation impact is 14.75: it has been cited 14.75 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism

  • pharmacogenetics
  • personalized medicine
  • drug-metabolizing enzymes
  • drug transporters
  • CYP2D6
  • CYP2C19
  • CYP2C9
  • thiopurine S-methyltransferase

Work with this paper

Most-cited papers in Pharmacology, Toxicology and Pharmaceutics

All highly cited Pharmacology, Toxicology and Pharmaceutics papers

Questions about this paper

How do I cite this paper in APA style?

Zhou, S., Di, Y. M., Chan, E., Du, Y., Chow, V., Xue, C. C., Lai, X., Wang, J., Li, C. G., Tian, M., & Duan, W. (2008). Clinical Pharmacogenetics and Potential Application in Personalized Medicine. Current Drug Metabolism, 9(8), 738–784. https://doi.org/10.2174/138920008786049302

How many times has this paper been cited?

239 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Figshare: sign in and open the full text from this page.

Who wrote this paper?

Shufeng Zhou, Yuan Ming Di, Elaine Chan, Yaomin Du, Vivian Chow, Charlie Changli Xue, Xinsheng Lai, Jiancheng Wang, Chun Guang Li, Min Tian, Wei Duan.

What is the DOI of this paper?

10.2174/138920008786049302, permanently at https://doi.org/10.2174/138920008786049302. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.